Skip to main content
. 2022 Jan 11;10(1):e003735. doi: 10.1136/jitc-2021-003735

Figure 2.

Figure 2

Expansion of OT-I cells is enhanced by mIgG1-N297A but impaired with mIgG2a anti-PD-1 mAbs. (A–F) Groups of C57BL/6 mice received OT-I cell transfer prior to intraperitoneal injection with 5 mg OVA alone or plus the indicated treatments on day 0. (A) Kinetics of SIINFEKL-specific CD8 T-cell expansion (shown as % of lymphocytes) after treatment with 100 µg anti-CD40 (CD40Hi), 10 µg anti-CD40 plus irrelevant mAbs (CD40Lo) or CD40Lo plus anti-PD-1 isotypes. (B) Example plots and percentage of SIINFEKL-specific CD8 T cells at day 5. (C–D) Expression of PD-1 (C) and frequency of CD62L+, CD44+ and double positive cells (D) in SIINFEKL-specific CD8 T cells at day 5. (E, F) Expression of PD-1 (E) and frequency of CD62L+, CD44+ and double positive cells (F) in tetramer negative CD8 T cells at day 5. (G) Percentage of SIINFEKL-specific CD8 T cells (as % of lymphocytes) at day seven following rechallenge with SIINFEKL peptide. Experiment performed twice, n=6–8 mice per group. Data in (C, E) show one representative experiment of two. Bars represent mean±SD. *P<0.05, **p<0.01, ***p<0.001 (one-way ANOVA). ANOVA, analysis of variance; mAbs, monoclonal antibodies; PD-1, programmed cell-death; OVA, ovalbumin.